Opioid Pharmacology

Correct Answer

C — Pure competitive antagonist at mu, kappa, and delta opioid receptors with no intrinsic agonist activity, used for acute overdose reversal

Rationale

Naloxone is a pure competitive opioid antagonist that binds with high affinity to mu, kappa, and delta receptors without activating them. It has no intrinsic agonist activity and produces no analgesia, sedation, or euphoria on its own. Its clinical role is acute reversal of opioid overdose — including the three components of the overdose triad: coma, miosis, and respiratory depression. A partial mu agonist with a ceiling effect on respiratory depression describes buprenorphine. A peripherally restricted mu antagonist for opioid-induced constipation describes methylnaltrexone or naloxegol. A full mu agonist with a long half-life used in opioid use disorder treatment describes methadone.

Correct Answer

A — Peripherally restricted mu opioid receptor antagonist that blocks gut opioid receptors to treat opioid-induced constipation without reversing central analgesia

Rationale

Methylnaltrexone is a quaternary ammonium derivative of naltrexone that carries a positive charge at physiological pH, limiting its ability to cross the blood-brain barrier. This peripheral restriction allows it to antagonize mu receptors in the gastrointestinal tract — restoring bowel motility suppressed by opioids — without entering the central nervous system in meaningful amounts. Because it spares central mu receptors, it treats opioid-induced constipation without reversing opioid analgesia or precipitating withdrawal. A pure mu/kappa/delta antagonist for acute overdose reversal describes naloxone. A partial mu agonist and kappa antagonist for opioid use disorder describes buprenorphine. A kappa agonist and mu antagonist for pruritus describes nalbuphine.

Correct Answer

D — Synthetic phenylpiperidine full mu opioid receptor agonist approximately 100 times more potent than morphine, now the leading cause of opioid overdose deaths through its presence in the illicit drug supply

Rationale

Fentanyl is a synthetic phenylpiperidine full mu opioid receptor agonist with approximately 100 times the potency of morphine by weight. Its extremely high potency means that very small quantities — invisible to the naked eye — can cause fatal respiratory depression. Illicitly manufactured fentanyl and its analogs are now adulterated into the heroin and counterfeit pill supply, driving the current overdose epidemic. Because fentanyl is a full mu agonist, it causes maximal respiratory depression with no ceiling effect, and its high potency means higher naloxone doses or repeated doses may be needed for reversal. A naturally occurring phenanthrene prodrug describes codeine. Fentanyl is not peripherally restricted. A partial mu agonist with a ceiling effect on respiratory depression describes buprenorphine.

Correct Answer

B — Pure opioid antagonist with longer duration than naloxone, available as daily oral tablets or monthly extended-release injection for maintenance treatment

Rationale

Naltrexone is a pure opioid antagonist structurally related to naloxone but with a substantially longer duration of action, making it suitable for once-daily oral dosing or monthly extended-release injectable administration. Unlike naloxone — used primarily for acute overdose reversal — naltrexone is used for long-term maintenance treatment of opioid use disorder and alcohol use disorder, blocking the rewarding effects of any opioid taken during the treatment period. A pure antagonist with a short duration used for acute reversal describes naloxone. A peripherally restricted antagonist for opioid-induced constipation describes methylnaltrexone or naloxegol. A kappa agonist and mu antagonist used for pain describes nalbuphine.

Correct Answer

A — Buprenorphine is a partial mu receptor agonist with a ceiling effect on respiratory depression — above a certain dose, additional buprenorphine does not produce additional respiratory suppression

Rationale

As a partial mu receptor agonist, buprenorphine activates the mu receptor but with submaximal intrinsic efficacy — it cannot produce the same degree of receptor activation as a full agonist regardless of dose. This creates a ceiling effect on respiratory depression: unlike full agonists, where respiratory depression increases proportionally with dose, buprenorphine's respiratory depressant effect plateaus at a level below that required to cause fatal apnea in most patients. This property makes buprenorphine substantially safer in accidental overdose compared to morphine, oxycodone, fentanyl, or methadone, and it is the pharmacological basis for its favorable safety profile in opioid use disorder treatment. Buprenorphine is not peripherally restricted — it crosses the blood-brain barrier. It has a long half-life, not a short one. It is a partial agonist, not a pure antagonist.

Correct Answer

D — Kappa opioid receptor agonist and mu opioid receptor antagonist that produces analgesia and is used to treat opioid-induced pruritus

Rationale

Nalbuphine is a mixed agonist-antagonist opioid: it activates kappa receptors (producing spinal analgesia and sedation) while blocking mu receptors. Its mu antagonism makes it useful for treating opioid-induced pruritus — by blocking mu receptors at the spinal cord level where pruritus is centrally mediated, it can reduce itching without fully reversing analgesia. Because of its mu antagonism, nalbuphine can precipitate withdrawal in patients who are physically dependent on full mu agonist opioids. A pure antagonist for overdose reversal describes naloxone. A peripherally restricted antagonist for constipation describes methylnaltrexone. A full mu agonist with high lipophilicity and rapid onset describes fentanyl.

Correct Answer

B — Mu receptor activation in brainstem respiratory centers reduces respiratory rate and blunts the normal drive to breathe in response to rising carbon dioxide levels

Rationale

Opioids cause respiratory depression through mu receptor activation in brainstem respiratory control centers, particularly the pre-Botzinger complex in the ventrolateral medulla, which generates the respiratory rhythm. Opioids reduce respiratory rate and blunt the normal response to rising carbon dioxide levels — shifting the carbon dioxide response curve rightward so that higher carbon dioxide concentrations are required to trigger a breath. Sleep compounds this risk by independently reducing the arousal response to hypercapnia. Because the same Gi/Go signaling that produces analgesia also acts in brainstem respiratory neurons, respiratory depression cannot be eliminated from opioid pharmacology at equianalgesic doses with currently available agents. Opioids do not cause bronchoconstriction via kappa receptors, do not paralyze respiratory muscles peripherally, and do not act primarily through delta receptors at the carotid body.

Correct Answer

C — Tolerance develops to the central nervous system effects of opioids including analgesia, but does not develop to the peripheral mu receptor-mediated effects on gastrointestinal motility

Rationale

Opioid tolerance — the requirement for increasing doses to maintain the original effect — develops to the central nervous system effects of opioids, including analgesia, euphoria, sedation, nausea, and respiratory depression. Tolerance does not develop to the peripheral gastrointestinal effects. Constipation is mediated by mu receptor activation in enteric neurons of the gastrointestinal tract, which reduces propulsive motility regardless of how long the patient has been on opioids. Prophylactic bowel regimens are therefore standard of care for any patient starting regular opioid therapy. Constipation is mediated by peripheral mu receptors, not kappa receptors. Oxycodone does not accumulate selectively in the gastrointestinal tract. Oxycodone is not converted to a gastrointestinal-selective metabolite.

Correct Answer

A — Unlike most other opioid central nervous system effects, tolerance does not substantially develop to miosis — it persists throughout chronic opioid therapy regardless of duration or dose

Rationale

Miosis results from mu receptor activation in the Edinger-Westphal nucleus of the oculomotor complex, which drives parasympathetic constriction of the pupillary sphincter. While tolerance develops to analgesia, euphoria, sedation, nausea, and respiratory depression, tolerance does not substantially develop to miosis. A patient who has been on stable opioid therapy for months or years will retain pinpoint pupils as long as they are taking opioids, even if their analgesic effect has diminished considerably. This makes miosis one of the most reliable clinical signs of ongoing opioid effect and a key element of the overdose triad. Miosis is a central nervous system effect mediated by the Edinger-Westphal nucleus, not by peripheral iris receptors. It is mediated by mu receptors, not kappa receptors. Tolerance to miosis does not develop and stabilize — it simply does not develop meaningfully at all.

Correct Answer

D — In tolerance, dose escalation restores pain control; in opioid-induced hyperalgesia, dose escalation worsens pain, and paradoxical improvement occurs with dose reduction

Rationale

The clinically critical distinction between tolerance and opioid-induced hyperalgesia lies in the response to dose escalation. With tolerance, the analgesic effect has diminished at the current dose, but increasing the dose restores adequate pain control. With opioid-induced hyperalgesia, the patient has become hypersensitive to pain as a paradoxical consequence of opioid exposure, and increasing the dose worsens pain rather than relieving it. A paradoxical improvement in pain when the opioid dose is reduced is the hallmark finding that should prompt consideration of opioid-induced hyperalgesia. Additional features of opioid-induced hyperalgesia include spread of pain beyond the original injury territory and allodynia — pain from stimuli that would not normally be painful. Constipation does not differentiate the two conditions. Miosis does not differentiate the two conditions. In opioid-induced hyperalgesia, pain spreads beyond the original site — the opposite of option C.

Correct Answer

B — Coma, miosis, and respiratory depression

Rationale

The opioid overdose triad consists of coma, miosis, and respiratory depression — three findings that reflect extreme mu receptor activation at brainstem and midbrain sites. Coma results from mu receptor activation suppressing the reticular activating system and thalamus. Miosis results from Edinger-Westphal nucleus activation driving parasympathetic pupillary constriction. Respiratory depression results from suppression of the pre-Botzinger complex and other brainstem respiratory centers. Respiratory depression is the primary cause of death. Miosis — not mydriasis — is the correct pupillary finding; mydriasis (pupillary dilation) suggests stimulant toxicity or co-ingestion of anticholinergic agents, which can mask opioid-induced miosis in mixed overdose. Opioid overdose produces hypotension, not hypertension. Seizures are not a component of the classic opioid overdose triad; they suggest normeperidine toxicity or a different toxidrome.

Correct Answer

C — Naloxone has a duration of action of 30 to 90 minutes, which is shorter than most opioids it reverses — as naloxone wears off, the precipitating opioid can reassert its effects and cause resedation

Rationale

The most critical pharmacokinetic limitation of naloxone is the mismatch between its short duration of action and the longer duration of most opioids it reverses. Naloxone's effects last only 30 to 90 minutes. If the precipitating opioid has a longer duration — as is the case with extended-release formulations, transdermal fentanyl, or methadone — the patient can relapse into respiratory depression and coma as the naloxone wears off while the opioid remains active at receptors. This resedation risk means that naloxone reversal does not end the medical emergency. The patient must be observed for the full duration of action of the precipitating opioid, and repeated naloxone doses or a continuous infusion may be needed. Naloxone does not produce toxic metabolites. It does not have protein binding interactions of the type described. Naloxone does not redistribute from adipose tissue in a clinically meaningful way.

Correct Answer

D — Opioid-induced pruritus is mediated centrally by mu receptor activation in the spinal cord, not by peripheral histamine release — antihistamines address only the histamine pathway

Rationale

Opioid-induced pruritus — particularly with neuraxial (epidural or intrathecal) opioid administration — is mediated centrally by mu receptor activation in the spinal cord dorsal horn rather than by peripheral histamine release. Because the mechanism is central and opioid receptor-mediated, antihistamines are at best partially effective. Low-dose naloxone infusions or the mixed agonist-antagonist nalbuphine can treat opioid-induced pruritus more effectively by blocking the mu receptor-mediated itch signal without fully reversing analgesia. Morphine does cause some peripheral histamine release from mast cells with rapid intravenous injection, but this is not the mechanism of neuraxial opioid-induced pruritus. Opioid-induced pruritus is mediated by mu receptors, not kappa receptors. The mechanism does not differ between morphine and fentanyl in the neuraxial setting.

Correct Answer

A — A large naloxone dose in an opioid-dependent patient fully displaces the opioid from receptors and precipitates acute withdrawal, causing agitation, vomiting, and cardiovascular stress — titrating avoids this while restoring adequate breathing

Rationale

In a patient who is physically dependent on opioids, rapid and complete opioid receptor blockade with a large naloxone dose precipitates acute withdrawal. Unlike the gradual development of withdrawal from opioid cessation, precipitated withdrawal is abrupt and severe: the patient awakens suddenly agitated, diaphoretic, vomiting, and in cardiovascular distress. The goal of naloxone titration in this setting is to restore adequate spontaneous ventilation — not to produce full arousal or complete opioid reversal. Starting with small incremental doses (0.04 to 0.1 mg intravenously) and titrating to a respiratory rate of at least 10 to 12 breaths per minute achieves the life-saving respiratory goal while minimizing the severity of precipitated withdrawal. Naloxone is not hepatotoxic. It does not permanently downregulate mu receptors. It does block kappa receptors, but the dysphoria described is not the reason to avoid large doses — precipitated withdrawal is the clinical concern.

Correct Answer

B — Co-ingestion of a stimulant or anticholinergic substance produced competing pupillary dilation that offset the opioid-induced miosis, masking the classic overdose triad finding

Rationale

The classic opioid overdose triad includes miosis, but in polydrug overdose — which is common in the illicit drug use setting — co-ingested substances can modify the clinical picture. Stimulants such as cocaine and amphetamines activate sympathetic pathways that dilate the pupil, competing with opioid-induced miosis. Anticholinergic drugs block the muscarinic receptors that mediate pupillary constriction, also producing dilation. The net pupillary finding reflects the balance of competing pharmacological forces. The response to naloxone in this case confirms opioid involvement despite the atypical pupillary finding. This case illustrates that absence of miosis does not exclude opioid overdose in a mixed ingestion. Tolerance does not develop to miosis — pinpoint pupils persist throughout chronic opioid therapy. All opioids that activate mu receptors produce miosis; kappa agonism does not cause mydriasis at clinically relevant doses. Fentanyl analogs produce miosis, not mydriasis, regardless of their lipophilicity.

Correct Answer

C — Naloxone's duration of action is shorter than that of extended-release oxycodone — as naloxone wears off, oxycodone still present at mu receptors reasserts respiratory depression

Rationale

This case demonstrates the half-life mismatch that makes naloxone reversal a temporizing measure rather than a definitive treatment. Naloxone's duration of action is 30 to 90 minutes. Extended-release oxycodone has a far longer effective duration, releasing drug continuously over hours. When the naloxone is eliminated, oxycodone continues to activate mu receptors and reasserts its respiratory depressant effect — producing the resedation seen approximately 75 minutes after initial reversal. This is the critical clinical lesson: successful naloxone reversal does not end the medical emergency. The patient must be observed for the full duration of the precipitating opioid's action, and repeat naloxone doses or a continuous infusion must be available. Naloxone does not have opioid-active metabolites. Extended-release formulations are designed to release drug over many hours, not all at once. Naloxone does not cause rebound endogenous opioid release.

Correct Answer

D — Reduce the morphine dose — the pattern of pain worsening with dose escalation and spread beyond the original territory suggests opioid-induced hyperalgesia rather than tolerance

Rationale

The clinical picture — pain worsening despite dose escalation, spread of pain beyond the original injury territory, and further worsening after the most recent dose increase — describes opioid-induced hyperalgesia rather than simple tolerance. In tolerance, dose escalation restores adequate pain control. In opioid-induced hyperalgesia, dose escalation worsens pain paradoxically because the opioid itself is now the pain-sensitizing agent. The appropriate management is opioid dose reduction or rotation to a different opioid at a reduced equianalgesic dose, combined with reassessment of the pain management strategy. Increasing the dose further or switching to a higher-potency full agonist at equianalgesic doses would worsen the hyperalgesia. Adding gabapentin may be part of an overall plan but does not address the fundamental problem of opioid-induced hyperalgesia driving worsening pain.

Correct Answer

A — Tolerance develops to the central nervous system effects of opioids including sedation and analgesia, but does not develop to miosis — pinpoint pupils persist throughout chronic opioid therapy

Rationale

The pattern in this patient — diminished analgesia and resolved sedation with persistent miosis — reflects the well-established difference in tolerance development across opioid effects. Tolerance develops to analgesia, euphoria, sedation, nausea, and respiratory depression. Tolerance does not develop to constipation or miosis. Miosis results from mu receptor activation in the Edinger-Westphal nucleus driving parasympathetic pupillary constriction, and this effect persists as long as the patient continues opioid therapy regardless of how long they have been on it. Persistent miosis in a patient on chronic opioids is an expected finding, not a sign of excess dosing. Miosis is mediated centrally by the Edinger-Westphal nucleus, not by peripheral iris receptors. Morphine-6-glucuronide does not have selective affinity for the Edinger-Westphal nucleus. Miosis in a chronic opioid patient does not indicate dose escalation beyond the prescribed amount.